Results 111 to 120 of about 187,458 (237)

Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice [PDF]

, 2002
Bruton's tyrosine kinase (Btk) is a cytoplasmic signaling molecule that is crucial for precursor (pre-B) cell differentiation in humans. In this study, we show that during the transition of large cycling to small resting pre-B cells in ...
Dingjan, G.M. (Gemma), Hendriks, R.W. (Rudi), Middendorp, S.   +2 more
core   +2 more sources

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).

Journal of Medicinal Chemistry, 2019
Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.
S. H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, D. Batt, Ling Li, M. Pattoli, S. Skala, Lihong Cheng, M. Obermeier, Robin Moore, Zheng Yang, R. Vickery, P. Elzinga, Lorell N. Discenza, C. D’arienzo, Kathleen M. Gillooly, T. Taylor, C. Pulicicchio, Yifan Zhang, Elizabeth M. Heimrich, K. McIntyre, Q. Ruan, R. Westhouse, I. Catlett, Naiyu Zheng, C. Chaudhry, Jun Dai, Michael A. Galella, A. Tebben, M. Pokross, Jianqing Li, R. Zhao, Daniel J. Smith, R. Rampulla, A. Allentoff, M. Wallace, A. Mathur, L. Salter-Cid, J. Macor, P. Carter, A. Fura, J. Burke, J. Tino   +42 more
semanticscholar   +1 more source

Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next

Photochemistry and Photobiology, EarlyView.
The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal, Durdana Muntaqua, Gagan Chhabra, Nihal Ahmad   +3 more
wiley   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.
What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

Controlling the Activity of the Tec Kinase Itk by Mutation of the Phenylalanine Gatekeeper Residue [PDF]

, 2010
The regulatory spine is a set of conserved residues that are assembled and disassembled upon activation and inactivation of kinases. We recently identified the regulatory spine within the immunologically important Tec family kinases and have shown that ...
Andreotti, Amy, Andreotti, Amy, Joseph, Raji   +2 more
core   +3 more sources

Targetable Vulnerabilities in MYC‐Driven B Cell Lymphomas Resistant to BCR Extinction

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Polatuzumab vedotin, an antibody‐drug conjugate (ADC) targeting the B cell receptor (BCR) signaling subunit CD79B, has recently entered frontline therapy for diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBCL), achieving encouraging clinical results. However, MYC‐driven B cell lymphomas, particularly HGBCL with MYC and
Silvia Brambillasca, Nicara Chantal Parr, Adriana Palmeri, Adrian Andronache, Hiroshi Arima, Giovanni Faga’, Brian Leuzzi, Laura Perucho, Michela Robusto, Maurizio Pasi, Federica Mainoldi, Daniele Fancelli, Mario Varasi, Gabriele Varano, Ciro Mercurio, Stefano Casola   +15 more
wiley   +1 more source

Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes

Stem Cell Reports, 2019
Summary: Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF).
Sanam Shafaattalab, Eric Lin, Effimia Christidi, Haojun Huang, Yulia Nartiss, Analucia Garcia, Jeehon Lee, Stephanie Protze, Gordon Keller, Liam Brunham, Glen F. Tibbits, Zachary Laksman   +11 more
doaj   +1 more source

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W., Campos, Carl, Clark, Owen, Codega, Paolo, DeAngelis, Lisa M., Dogan, Ahmet, Gavrilovic, Igor T., Glass, Jon, Graeber, Thomas G., Grommes, Christian, Gutin, Philip H., Hamlin, Paul, Hatzoglou, Vaios, Hsieh, Wan-Ying, Huse, Jason T., Kaley, Thomas J., Lallana, Enrico C., Mellinghoff, Ingo K., Moskowitz, Craig H., Nichol, Donna, Nolan, Craig P., Noy, Ariela, Omuro, Antonio, Palaskas, Nicolaos, Palomba, M. Lia, Panageas, Katherine S., Pastore, Alessandro, Peak, Scott, Pentsova, Elena, Reiner, Anne S., Rohle, Dan, Rosenblum, Marc, Sauter, Craig S., Schartz, Derrek, Schultz, Nikolaus, Tabar, Viviane S., Tang, Sarah S., Thomas, Alissa A., Tsyvkin, Elina, Viale, Agnes, Wolfe, Julia, Won, Minhee   +41 more
core   +2 more sources

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source